Focal Pulmonary Uptake During Tc-99m Myocardial Perfusion SPECT Imaging

Purpose To evaluate the incidence and origin of abnormal focal pulmonary uptake during myocardial perfusion SPECT imaging (MSPECT). Methods For evaluation of chest pain, 790 men and 581 women (mean age, 56 ± 13 years) underwent MSPECT. All of them received adenosine for pharmacologic stress and Tc-99m tetrofosmin (TF, n = 817) or Tc-99m sestamibi (MIBI, n = 554) for myocardial perfusion imaging. Results Review of chest radiography with or without computed tomography revealed 111 (8.1%) focal pulmonary diseases. Among them, 38 (34.2%) showed focal pulmonary uptake (TF, 22; MIBI, 16); 27 (30.7%) of 88 showed previous pulmonary tuberculosis; 2 of 10 (20%) benign pulmonary nodules; 4 of 5 (80%) metastatic lung cancers; 2 of 4 (50%) primary lung cancers; and 3 of 4 (75%) pneumonias. No difference in uptake was noted for the two imaging agents. Intensity of uptake did not vary with origin of the uptake. Focal abnormal pulmonary uptake was found in 2.8% of patients undergoing MSPECT and in 34.2% of patients in whom radiological examinations showed regional pulmonary disease. In patients with abnormal pulmonary uptake on MSPECT, 16% had a malignant lesion, whereas 75% of patients with a pulmonary nodule shown on radiography and focal pulmonary uptake on MSPECT had a malignant lesion. Conclusions Although the incidence of abnormal pulmonary uptake during MSPECT was very low, the incidence of malignant lesions in the patients with nodular pulmonary uptake was relatively high.

[1]  H. Schicha,et al.  Use of myocardial imaging agents for tumour diagnosis – a success story? , 2000, European Journal of Nuclear Medicine.

[2]  A. Mehta,et al.  Role of Tc-99m MIBI in the evaluation of single pulmonary nodules: a preliminary report , 2000, Thorax.

[3]  E. Uçan,et al.  Technetium-99m-tetrofosmin scintigraphy in pulmonary tuberculosis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  F. Barral,et al.  Technetium-99m sestamibi brain single-photon emission tomography for detection of recurrent gliomas after radiation therapy , 1998, European Journal of Nuclear Medicine.

[5]  A. Rastogi,et al.  Tc-99m MIBI thoracic SPECT for the detection of intrathoracic tumor masses. , 1998, Clinical nuclear medicine.

[6]  T. Yen,et al.  Technetium‐99m methoxyisobutylisonitrile chest imaging of small cell lung carcinoma , 1998, Cancer.

[7]  T. Atasever,et al.  Primary large cell neuroendocrine carcinoma: a cause of extracardiac uptake site of Tc99m tetrofosmin. , 1998, Seminars in nuclear medicine.

[8]  H. Bom,et al.  Technetium-99m-MIBI uptake in small cell lung cancer. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  Ç. Onsel,et al.  Technetium-99m-MIBI scintigraphy in pulmonary tuberculosis. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[10]  Q. Sun,et al.  99Tcm-MIBI mammoscintigraphy of breast masses: early and delayed imaging. , 1995, Nuclear medicine communications.

[11]  C. Rush,et al.  Liver metastases detected by Tc-99m sestamibi during routine cardiac imaging. , 1995, Clinical nuclear medicine.

[12]  H. Bom,et al.  Tc‐99m MIBI Uptake in Simultaneous Thyroid and Lung Cancers , 1994, Clinical nuclear medicine.

[13]  S. Treves,et al.  Thallium-201 versus technetium-99m-MIBI SPECT in evaluation of childhood brain tumors: a within-subject comparison. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  M. Kır,et al.  Technetium-99m-MIBI and thallium-201 uptake in pulmonary actinomycosis. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  H. Abdel-Dayem,et al.  Uptake and Kinetics of Tc-99m Hexakis 2-Methoxy Isobutyl Isonitrile in Benign and Malignant Lesions in the Lungs , 1989, Clinical nuclear medicine.